Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Robert De Jager"'
Autor:
Howard W. Bruckner, Robert De Jager, Elisheva Knopf, Fred Bassali, Abe Book, Daniel Gurell, Van Nghiem, Myron Schwartz, Azriel Hirschfeld
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionRoutine blood tests are prognostic tests for patients with cholangiocarcinoma. New drug regimens may produce a median overall survival of 2 years or more.MethodsThis single practice, IRB-approved, phase II trial examines prognostic tests,
Externí odkaz:
https://doaj.org/article/2637638aaaa648f89987db28e96e8e32
Publikováno v:
PLoS ONE, Vol 17, Iss 11, p e0276492 (2022)
BackgroundPatients have difficult unmet needs when standard chemotherapy produces a median survival of less than 1 year or many patients will experience severe toxicities. Blood tests can predict their survival.MethodsAnalyses evaluate predictive blo
Externí odkaz:
https://doaj.org/article/3c944f62ff1d403c833c8697bc85b3a4
Autor:
Mikhail S. Shchepinov, Frederic Heerinckx, Marcus W. Kilpatrick, Robert De Jager, Omid Omidvar, Theresa A. Zesiewicz, Jessica D. Shaw
Publikováno v:
Movement Disorders. 33:1000-1005
Background RT001 is a deuterated ethyl linoleate that inhibits lipid peroxidation and is hypothesized to reduce cellular damage and recover mitochondrial function in degenerative diseases such as Friedreich's ataxia. Objective To evaluate the safety,
Autor:
AJ Book, Daniel Gurell, Azriel Hirschfeld, Howard W. Bruckner, Myron Schwartz, Robert De Jager, Van T. Nghiem, Fred Bassali, Shoshana Distenfeld
Publikováno v:
Journal of Clinical Oncology. 39:e16160-e16160
e16160 Background: Advanced (Adv) intrahepatic IH Cholangiocarcinoma BD trials found multi-drug, sequences (GFLIO) safely expand eligibility (El) for patients (pts) of all ages -/+ resistant Ca (R). Two series had response/survival (S) of 80% / > 2 y
Autor:
AJ Book, Howard W. Bruckner, Shoshana Distenfeld, Fred Bassali, Robert De Jager, Azriel Hirschfeld, Elisheva Dusowitz
Publikováno v:
Journal of Clinical Oncology. 39:e16158-e16158
e16158 Background: A sequence of drug combinations produces > 1 median (M) -strong 2-year (yr) survival (S) (Bruckner et al AACR 14 Antica Res (ACR) 16, 18 SIGO 19). Trials included high-risk patients (pts). Each initial series has 5-yr Ss, after pts
Volume 1 of 2. Coleridge's Shorter Works and Fragments brings together a number of substantial essays that were not long enough to require volumes to themselves, among them his'Theory of Life,''Essays on the Principles of Genial Criticism,''Treatise
Autor:
Howard W. Bruckner, Robert De Jager, Shoshana Distenfeld, Fred Bassali, Azriel Hirschfeld, Van T. Nghiem, AJ Book, Noah Weinberger, Daniel Gurell
Publikováno v:
Journal of Clinical Oncology. 38:e16763-e16763
e16763 Background: Gemcitabine (G), 5-fluorouracil (F), leucovorin (L), irinotecan (I), and oxaliplatin (O), (GFLIO) is safe, employs moderate 1/2-1/3 dosages, offers expanded eligibility (0-2 ECOG PS; no age limit)). Each step reverse resistance (RR
Autor:
Theresa, Zesiewicz, Frederic, Heerinckx, Robert, De Jager, Omid, Omidvar, Marcus, Kilpatrick, Jessica, Shaw, Mikhail S, Shchepinov
Publikováno v:
Movement disorders : official journal of the Movement Disorder Society. 33(6)
RT001 is a deuterated ethyl linoleate that inhibits lipid peroxidation and is hypothesized to reduce cellular damage and recover mitochondrial function in degenerative diseases such as Friedreich's ataxia.To evaluate the safety, pharmacokinetics, and
Autor:
Robert De Jager, Harry J. Saal, Theresa A. Zesiewicz, Frederic Heerinckx, Tanya V. Aranca, Robert LeMoyne
Publikováno v:
BSN
The integration of wearable and wireless inertial body sensors with machine learning offers the capacity to diagnose neurological disorders involving gait. Clinical rating scales may be unable to offer precise measurement of gait dysfunction in Fried